Drug
Alagebrium clinical trials
Also written ALT-711.
- studies test it
- 13
- open now
- 0
- in phase 3
- 1
- first study started
- 2001
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 13
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
Synvista Therapeutics, Inc (10) · University of Texas Southwestern Medical Center (1) · Radboud University Medical Center (1) · Cardiovascular Clinical Sciences Inc (1)
Studies
Open first, then newest update. How each study uses alagebrium is read from its arms, and is right about nine times in ten.
Testing it · 13
- The Effect of Exercise and Alagebrium on the Diastolic Function of the HeartCompletedPhase 2University of Texas Southwestern Medical CenterNCT01014572Written as Alagebrium (generic: ALT-711)
- Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and FunctionCompletedPhase 2/3Radboud University Medical CenterNCT01417663Written as Alt-711
- A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart FailureTerminatedPhase 2Cardiovascular Clinical Sciences IncNCT01913301Written as Alagebrium
- The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)CompletedPhase 2Synvista Therapeutics, IncNCT00045981Written as ALT-711
- Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)TerminatedPhase 2Synvista Therapeutics, IncNCT00089713Written as alagebrium chloride (ALT-711)
- The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart FailureCompletedPhase 2Synvista Therapeutics, IncNCT00516646Written as ALT-711
- The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart FailureCompletedPhase 2Synvista Therapeutics, IncNCT00043836Written as ALT-711
- STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISHCompletedPhase 2Synvista Therapeutics, IncNCT00277875Written as ALT-711 (alagebrium chloride)
- The SILVER Study: Systolic Hypertension Interaction With Left Ventricular RemodelingCompletedPhase 2Synvista Therapeutics, IncNCT00045994Written as ALT-711
- Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)TerminatedPhase 2Synvista Therapeutics, IncNCT00662116Written as alagebrium
- Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and MicroalbuminuriaTerminatedPhase 2Synvista Therapeutics, IncNCT00557518Written as Alagebrium
- Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart FailureTerminatedPhase 2Synvista Therapeutics, IncNCT00739687Written as ALT-711
- The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic HypertensionCompletedPhase 2Synvista Therapeutics, IncNCT00302250Written as ALT-711 (alagebrium chloride)
Codes
What other systems call alagebrium · ClinicalTrials.gg INT004228
- MeSH (NLM) C406794alagebriumOne source NLM
- UNII (FDA) DGH49JXB1FALAGEBRIUMConfirmed NLM, Wikidata
- Wikidata Q27276389alagebriumConfirmed NLM, Wikidata
- DrugBank DB12497One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C406794 | alagebrium | One source NLM |
| UNII (FDA) | DGH49JXB1F | ALAGEBRIUM | Confirmed NLM, Wikidata |
| Wikidata | Q27276389 | alagebrium | Confirmed NLM, Wikidata |
| DrugBank | DB12497 | — | One source Wikidata |
Also registered as alagebrium chloride (UNII 79QS8K2877).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.